Subcellular localization of activated AKT in estrogen receptor- and progesterone receptor-expressing breast cancers

Potential clinical implications

Sunil Badve, Nikail R. Collins, Poornima Bhat-Nakshatri, Dmitry Turbin, Samuel Leung, Mangesh Thorat, Sandra E. Dunn, Tim R. Geistlinger, Jason S. Carroll, Myles Brown, Shikha Bose, Michael A. Teitell, Harikrishna Nakshatri

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Activated v-AKT murine thymoma viral oncogene homolog 1 (AKT)/protein kinase B (PKB) kinase (pAKT) is localized to the plasma membrane, cytoplasm, and/or nucleus in 50% of cancers. The clinical importance of pAKT localization and the mechanism(s) controlling this compartmentalization are unknown. In this study, we examined nuclear and cytoplasmic phospho-AKT (pAKT) expression by immunohistochemistry in a breast cancer tissue microarray (n = 377) with ≈15 years follow-up and integrated these data with the expression of estrogen receptor (ER)α, progesterone receptor (PR), and FOXA1. Nuclear localization of pAKT (nuclear-pAKT) was associated with long-term survival (P = 0.004). Within the ERα+/PR+ subgroup, patients with nuclear-pAKT positivity had better survival than nuclear-pAKT-negative patients (P ≤ 0.05). The association of nuclear-pAKT with the ERα+/PR+ subgroup was validated in an independent cohort (n = 145). TCL1 family proteins regulate nuclear transport and/or activation of AKT. TCL1B is overexpressed in ERα-positive compared with ERα-negative breast cancers and in lung metastasis-free breast cancers. Therefore, we examined the possible control of TCL1 family member(s) expression by the estrogen:ERα pathway. Estradiol increased TCL1B expression and increased nuclear-pAKT levels in breast cancer cells; short- interfering RNA against TCL1B reduced nuclear-pAKT. Overexpression of nuclear-targeted AKT1 in MCF-7 cells increased cell proliferation without compromising sensitivity to the anti-estrogen, tamoxifen. These results suggest that subcellular localization of activated AKT plays a significant role in determining its function in breast cancer, which in part is dependent on TCL1B expression.

Original languageEnglish
Pages (from-to)2139-2149
Number of pages11
JournalAmerican Journal of Pathology
Volume176
Issue number5
DOIs
StatePublished - May 2010

Fingerprint

Progesterone Receptors
Estrogen Receptors
Breast Neoplasms
Estrogens
Proto-Oncogene Proteins c-akt
Thymoma
Survival
Cell Nucleus Active Transport
MCF-7 Cells
Tamoxifen
Oncogenes
Small Interfering RNA
Estradiol
Lung Neoplasms
Cytoplasm
Phosphotransferases
Immunohistochemistry
Cell Proliferation
Cell Membrane
Neoplasm Metastasis

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Subcellular localization of activated AKT in estrogen receptor- and progesterone receptor-expressing breast cancers : Potential clinical implications. / Badve, Sunil; Collins, Nikail R.; Bhat-Nakshatri, Poornima; Turbin, Dmitry; Leung, Samuel; Thorat, Mangesh; Dunn, Sandra E.; Geistlinger, Tim R.; Carroll, Jason S.; Brown, Myles; Bose, Shikha; Teitell, Michael A.; Nakshatri, Harikrishna.

In: American Journal of Pathology, Vol. 176, No. 5, 05.2010, p. 2139-2149.

Research output: Contribution to journalArticle

Badve, S, Collins, NR, Bhat-Nakshatri, P, Turbin, D, Leung, S, Thorat, M, Dunn, SE, Geistlinger, TR, Carroll, JS, Brown, M, Bose, S, Teitell, MA & Nakshatri, H 2010, 'Subcellular localization of activated AKT in estrogen receptor- and progesterone receptor-expressing breast cancers: Potential clinical implications', American Journal of Pathology, vol. 176, no. 5, pp. 2139-2149. https://doi.org/10.2353/ajpath.2010.090477
Badve, Sunil ; Collins, Nikail R. ; Bhat-Nakshatri, Poornima ; Turbin, Dmitry ; Leung, Samuel ; Thorat, Mangesh ; Dunn, Sandra E. ; Geistlinger, Tim R. ; Carroll, Jason S. ; Brown, Myles ; Bose, Shikha ; Teitell, Michael A. ; Nakshatri, Harikrishna. / Subcellular localization of activated AKT in estrogen receptor- and progesterone receptor-expressing breast cancers : Potential clinical implications. In: American Journal of Pathology. 2010 ; Vol. 176, No. 5. pp. 2139-2149.
@article{102f1441f27949a9b786fca5235d7299,
title = "Subcellular localization of activated AKT in estrogen receptor- and progesterone receptor-expressing breast cancers: Potential clinical implications",
abstract = "Activated v-AKT murine thymoma viral oncogene homolog 1 (AKT)/protein kinase B (PKB) kinase (pAKT) is localized to the plasma membrane, cytoplasm, and/or nucleus in 50{\%} of cancers. The clinical importance of pAKT localization and the mechanism(s) controlling this compartmentalization are unknown. In this study, we examined nuclear and cytoplasmic phospho-AKT (pAKT) expression by immunohistochemistry in a breast cancer tissue microarray (n = 377) with ≈15 years follow-up and integrated these data with the expression of estrogen receptor (ER)α, progesterone receptor (PR), and FOXA1. Nuclear localization of pAKT (nuclear-pAKT) was associated with long-term survival (P = 0.004). Within the ERα+/PR+ subgroup, patients with nuclear-pAKT positivity had better survival than nuclear-pAKT-negative patients (P ≤ 0.05). The association of nuclear-pAKT with the ERα+/PR+ subgroup was validated in an independent cohort (n = 145). TCL1 family proteins regulate nuclear transport and/or activation of AKT. TCL1B is overexpressed in ERα-positive compared with ERα-negative breast cancers and in lung metastasis-free breast cancers. Therefore, we examined the possible control of TCL1 family member(s) expression by the estrogen:ERα pathway. Estradiol increased TCL1B expression and increased nuclear-pAKT levels in breast cancer cells; short- interfering RNA against TCL1B reduced nuclear-pAKT. Overexpression of nuclear-targeted AKT1 in MCF-7 cells increased cell proliferation without compromising sensitivity to the anti-estrogen, tamoxifen. These results suggest that subcellular localization of activated AKT plays a significant role in determining its function in breast cancer, which in part is dependent on TCL1B expression.",
author = "Sunil Badve and Collins, {Nikail R.} and Poornima Bhat-Nakshatri and Dmitry Turbin and Samuel Leung and Mangesh Thorat and Dunn, {Sandra E.} and Geistlinger, {Tim R.} and Carroll, {Jason S.} and Myles Brown and Shikha Bose and Teitell, {Michael A.} and Harikrishna Nakshatri",
year = "2010",
month = "5",
doi = "10.2353/ajpath.2010.090477",
language = "English",
volume = "176",
pages = "2139--2149",
journal = "American Journal of Pathology",
issn = "0002-9440",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Subcellular localization of activated AKT in estrogen receptor- and progesterone receptor-expressing breast cancers

T2 - Potential clinical implications

AU - Badve, Sunil

AU - Collins, Nikail R.

AU - Bhat-Nakshatri, Poornima

AU - Turbin, Dmitry

AU - Leung, Samuel

AU - Thorat, Mangesh

AU - Dunn, Sandra E.

AU - Geistlinger, Tim R.

AU - Carroll, Jason S.

AU - Brown, Myles

AU - Bose, Shikha

AU - Teitell, Michael A.

AU - Nakshatri, Harikrishna

PY - 2010/5

Y1 - 2010/5

N2 - Activated v-AKT murine thymoma viral oncogene homolog 1 (AKT)/protein kinase B (PKB) kinase (pAKT) is localized to the plasma membrane, cytoplasm, and/or nucleus in 50% of cancers. The clinical importance of pAKT localization and the mechanism(s) controlling this compartmentalization are unknown. In this study, we examined nuclear and cytoplasmic phospho-AKT (pAKT) expression by immunohistochemistry in a breast cancer tissue microarray (n = 377) with ≈15 years follow-up and integrated these data with the expression of estrogen receptor (ER)α, progesterone receptor (PR), and FOXA1. Nuclear localization of pAKT (nuclear-pAKT) was associated with long-term survival (P = 0.004). Within the ERα+/PR+ subgroup, patients with nuclear-pAKT positivity had better survival than nuclear-pAKT-negative patients (P ≤ 0.05). The association of nuclear-pAKT with the ERα+/PR+ subgroup was validated in an independent cohort (n = 145). TCL1 family proteins regulate nuclear transport and/or activation of AKT. TCL1B is overexpressed in ERα-positive compared with ERα-negative breast cancers and in lung metastasis-free breast cancers. Therefore, we examined the possible control of TCL1 family member(s) expression by the estrogen:ERα pathway. Estradiol increased TCL1B expression and increased nuclear-pAKT levels in breast cancer cells; short- interfering RNA against TCL1B reduced nuclear-pAKT. Overexpression of nuclear-targeted AKT1 in MCF-7 cells increased cell proliferation without compromising sensitivity to the anti-estrogen, tamoxifen. These results suggest that subcellular localization of activated AKT plays a significant role in determining its function in breast cancer, which in part is dependent on TCL1B expression.

AB - Activated v-AKT murine thymoma viral oncogene homolog 1 (AKT)/protein kinase B (PKB) kinase (pAKT) is localized to the plasma membrane, cytoplasm, and/or nucleus in 50% of cancers. The clinical importance of pAKT localization and the mechanism(s) controlling this compartmentalization are unknown. In this study, we examined nuclear and cytoplasmic phospho-AKT (pAKT) expression by immunohistochemistry in a breast cancer tissue microarray (n = 377) with ≈15 years follow-up and integrated these data with the expression of estrogen receptor (ER)α, progesterone receptor (PR), and FOXA1. Nuclear localization of pAKT (nuclear-pAKT) was associated with long-term survival (P = 0.004). Within the ERα+/PR+ subgroup, patients with nuclear-pAKT positivity had better survival than nuclear-pAKT-negative patients (P ≤ 0.05). The association of nuclear-pAKT with the ERα+/PR+ subgroup was validated in an independent cohort (n = 145). TCL1 family proteins regulate nuclear transport and/or activation of AKT. TCL1B is overexpressed in ERα-positive compared with ERα-negative breast cancers and in lung metastasis-free breast cancers. Therefore, we examined the possible control of TCL1 family member(s) expression by the estrogen:ERα pathway. Estradiol increased TCL1B expression and increased nuclear-pAKT levels in breast cancer cells; short- interfering RNA against TCL1B reduced nuclear-pAKT. Overexpression of nuclear-targeted AKT1 in MCF-7 cells increased cell proliferation without compromising sensitivity to the anti-estrogen, tamoxifen. These results suggest that subcellular localization of activated AKT plays a significant role in determining its function in breast cancer, which in part is dependent on TCL1B expression.

UR - http://www.scopus.com/inward/record.url?scp=77952077124&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952077124&partnerID=8YFLogxK

U2 - 10.2353/ajpath.2010.090477

DO - 10.2353/ajpath.2010.090477

M3 - Article

VL - 176

SP - 2139

EP - 2149

JO - American Journal of Pathology

JF - American Journal of Pathology

SN - 0002-9440

IS - 5

ER -